Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel: Cutaneous T-Cell Lymphoma

Explore the latest updates and expert interviews

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Welcome to The Cutaneous T-Cell Lymphoma (CTCL) Channel

VJHemOnc brings you important developments in the field of CTCL presented by esteemed experts from around the world. The CTCL Channel offers exclusive video interviews as well as podcasts and in-depth roundtable discussions so you can keep up with the latest wherever you are.

The CTCL Channel covers all key research areas including insightful views on managing Sézary syndrome, systemic therapies including antibody-drug conjugates, novel clinical trial data, and much more.

Real-world barriers to treatment access in T-cell lymphoma 3:01
Real-world barriers to treatment access in T-cell lymphoma
Christina Poh • 11 Dec 2025
Pembrolizumab and pralatrexate for R/R peripheral T-cell lymphomas 4:02
Pembrolizumab and pralatrexate for R/R peripheral T-cell lymphomas
Christina Poh • 11 Dec 2025
Investigating novel therapeutic approaches for T-cell lymphoma 1:01
Investigating novel therapeutic approaches for T-cell lymphoma
Yumeng Zhang • 8 Dec 2025
Durvalumab plus lenalidomide versus single-agent durvalumab for refractory/advanced CTCL 2:38
Durvalumab plus lenalidomide versus single-agent durvalumab for refractory/advanced CTCL
Christiane Querfeld • 20 Jun 2025
DR-01, an anti-CD94 monoclonal antibody, in the treatment of ultra-rare cytotoxic T-cell lymphomas 1:38
DR-01, an anti-CD94 monoclonal antibody, in the treatment of ultra-rare cytotoxic T-cell lymphomas
Swaminathan Iyer • 9 Dec 2024
HRQoL in patients with R/R CTCL treated with lacutamab in the TELLOMAK trial 5:21
HRQoL in patients with R/R CTCL treated with lacutamab in the TELLOMAK trial
Pierluigi Porcu • 9 Dec 2024
The current standard of care for CTCL 3:46
The current standard of care for CTCL
Pierluigi Porcu • 9 Dec 2024
Assessing a 4-weekly dosing schedule of mogamulizumab in pts with mycosis fungoides/Sézary syndrome 2:50
Assessing a 4-weekly dosing schedule of mogamulizumab in pts with mycosis fungoides/Sézary syndrome
Christiane Querfeld • 8 Dec 2024
Phase II trial of durvalumab + lenalidomide vs single-agent durvalumab in refractory/advanced CTCL 3:41
Phase II trial of durvalumab + lenalidomide vs single-agent durvalumab in refractory/advanced CTCL
Christiane Querfeld • 8 Dec 2024
Lacutamab, an anti-KIR3DL2 monoclonal antibody, in the treatment of R/R PTCL 2:57
Lacutamab, an anti-KIR3DL2 monoclonal antibody, in the treatment of R/R PTCL
Swaminathan Iyer • 11 Dec 2023
KT-333: a first-in-class STAT3 degrader 1:36
KT-333: a first-in-class STAT3 degrader
Aditi Shastri • 8 Dec 2023
The current SOC in CTCL: skin-directed therapy, systemic therapy & clinical challenges 3:00
The current SOC in CTCL: skin-directed therapy, systemic therapy & clinical challenges
Pierluigi Porcu • 16 Jun 2023
Exciting research in CTCL: genomics, the tumor microenvironment and the potential role of MRD 2:49
Exciting research in CTCL: genomics, the tumor microenvironment and the potential role of MRD
Pierluigi Porcu • 16 Jun 2023
Lacutamab in patients with advanced mycosis fungoides: results from the TELLOMAK trial 3:18
Lacutamab in patients with advanced mycosis fungoides: results from the TELLOMAK trial
Pierluigi Porcu • 16 Jun 2023
Improving patient outcomes in CTCL: clinical collaboration and novel agents 1:20
Improving patient outcomes in CTCL: clinical collaboration and novel agents
Wendy Osborne • 24 Apr 2023
RadVax trial: nivolumab and low-dose radiation in patients with R/R Hodgkin lymphoma 3:30
RadVax trial: nivolumab and low-dose radiation in patients with R/R Hodgkin lymphoma
Michael LaRiviere • 11 Dec 2022

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

Diamond Supporter

AstraZeneca

Gold Supporter

Johnson & Johnson

Silver Supporter

Takeda

Bronze Supporter

Galapagos

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

If you are interested in becoming a supporter of The Lymphoma Channel, please contact us.

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals